[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632913":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":24,"locations":29,"responsibleParty":50,"collaborators":24,"id":52,"slug":24,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":24,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":24,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":31,"whyStopped":24,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Midazolam - Ketamine Group","EXPERIMENTAL","Drug",[13],"Drug: Midazolam + Ketamine",{"label":15,"type":10,"description":11,"interventionNames":16},"Dexmedetomidine",[17],"Drug: Dexmedetomidine (DEX)",[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Midazolam + Ketamine","Participants will receive intravenous midazolam (0.05 mg\u002Fkg) combined with ketamine (1 mg\u002Fkg). Supplemental ketamine doses (0.5 mg\u002Fkg) will be administered as needed to maintain adequate deep sedation during burn-related procedures.",[9],null,{"type":20,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Dexmedetomidine (DEX)","Participants will receive intravenous dexmedetomidine (loading dose 1 mcg\u002Fkg over 15 minutes, followed by infusion 0.5-1 mcg\u002Fkg\u002Fhour) adjusted to maintain adequate deep sedation during burn-related procedures.",[15],[30],{"facility":5,"status":31,"city":32,"state":24,"zip":24,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Cairo","Egypt","EG",{"type":36,"coordinates":37},"Point",[38,39],31.24967,30.06263,{"lat":39,"lon":38},[42,47],{"name":43,"role":44,"phone":45,"phoneExt":24,"email":46},"Hebatalla M Ahmed, Masters degree","CONTACT","00201155859990","hebatallamaged@med.asu.edu.eg",{"name":48,"role":49,"phone":24,"phoneExt":24,"email":24},"Hebatalla M Ahmed, Masters Degree","PRINCIPAL_INVESTIGATOR",{"type":51,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100632913",false,"NCT07519863","The Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients","Inclusion Criteria:\n\n* Age from 3 to 16 years\n* Both sexes\n* Patients classified as American Society of Anesthesiologists (ASA) Physical -Status I-II\n* Patients scheduled for elective burn-related procedures (e.g., burn dressing changes or minor interventions)\n\nExclusion Criteria:\n\n* Refusal or inability to provide written informed consent from parent or legal guardian\n* Known allergy or hypersensitivity to any of the study medications (midazolam, ketamine, or dexmedetomidine)\n* Presence of hepatic dysfunction\n* Presence of renal dysfunction\n* Presence of immunological or hematological disorders\n* History of epilepsy, developmental delay (mental retardation), or neurological deficits\n* Patients receiving or requiring high doses of inotropes and\u002For vasopressors intraoperatively or postoperatively\n* Preoperative hemodynamic instability, defined as uncontrolled hypertension, hypotension, or bradycardia","ALL","3 Years","16 Years",{"count":61,"type":62},60,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","The aim of this study is to compare the effects of dormicum-ketamine versus dexmedetomidine on postoperative emergence delirium in pediatric patients undergoing deep sedation for burn-related procedures",[68],"Emergence Delirium in Pediatric Anesthesia",[15,70],"Burn Procedural sedation","2026-04-02",{"date":73,"type":74},"2026-04-09","ACTUAL",{"date":76,"type":74},"2025-11-20",{"date":78,"type":62},"2026-12",{"name":5,"class":6},1]